OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY - Wang, L.; Li, J.; Xu, D.; Fang, J.; Van Vollenhoven, R.; Zhang, F. (Annals of the rheumatic diseases, 2023)
Keywords: Adverse events; Anti-DNA antibodies; APRIL protein; BLyS protein; CD19 antigen; Clinical Trials; Fc receptors; Fusion protein; Gastroenteritis; Herpes zoster; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Infections; Lupus; Lymphocytes B; Missing data; Patients; Placebos; Randomized control trial; Respiratory tract diseases; Response rates; Rhinopharyngitis; Safety; Scientific Abstracts; Systemic lupus erythematosus; Urinary tract; Randomized control trial; Clinical Trials; Systemic lupus erythematosus